Developments, news and strategies for drug development specific to phase I through Phase III global clinical trial management, execution, project management and outsourcing. Go→
News, articles and issues specific to clinical trial practice and implementation at the investigative site level. Go→
News, developments and strategies related to eClinical, data management, data collection, ePRO, and more information technology used in the drug development chain. Go→
News, articles and issues specific to laboratories role in the clinical trial, including ECG, imaging, genotyping, tissue samples and more. Go→
News, developments and strategies for clinical trials conduct in relation to the FDA, EMEA and other global regulatory authorities overseeing the drug development industry. Go→
News, articles and strategies related to clinical trial design which impact postmarketing studies, therapeutic areas, adaptive trials, statistics, protocols and more. Go→
PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that its Chairman and CEO, Josef von Rickenbach, has been named 2013 chairman of the Association of Clinical Research Organizations (ACRO).
Since its founding in 2002, ACRO has been committed to highlighting CRO expertise in all aspects of the clinical research enterprise. ACRO represents the CRO industry globally to pharmaceutical, biotech and medical device companies, regulators and legislators, peer associations, academic organizations, patient groups, the media and the public.
“It is an honor to have been selected to lead ACRO’s Board of Directors in 2013,” said Mr. von Rickenbach. “As incoming chairman, I look forward to continuing the great momentum initiated by my predecessor to help ACRO and its members build and strengthen public understanding and confidence in clinical research. Equally, I welcome the opportunity to collaborate with the association’s global stakeholders to promote the strategic value of clinical outsourcing, drive innovation in the drug development process and ensure the safe and ethical development of new medicines and treatments.”
Mr. von Rickenbach has taken PAREXEL from pioneering beginnings as one of the first clinical research organizations in the early 1980s to its place today as one of the top three public biopharmaceutical services providers. As Chairman and CEO of PAREXEL, he was one of the first to define the clinical research services sector. To make clinical development more effective for clients, he conceived a multidisciplinary and systems-oriented approach to outsourced clinical development, bringing efficiencies, scalability, and standardization to the process.
Mr. von Rickenbach previously served as Chair of ACRO in 2005 and is a long-standing member of the ACRO Board of Directors. He also serves on the Board of Directors of the New England Healthcare Institute. He holds a B.S. degree in Business Economics from the School of Business at the Lucerne University of Applied Sciences in Switzerland, and a Master of Business Administration degree from Harvard Business School.